PAR · ALVIO.PA
Valerio Therapeutics S.A.
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
Loading market information…
PAR · ALGEN.PA · EUR
Stock price
Quote as of Oct 29, 2026, 04:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
genOway S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
genOway S.A. is a global biotechnology enterprise that specializes in the creation, production, commercialization, and distribution of custom genetically engineered mouse, rat, and cell line models. The company develops bespoke mouse models, including knockout (KO) and knock-in (KI) types, along with customized rat models featuring constitutive and conditional KO, point mutation KI, and rapid KI options. They also engineer custom cell lines, offering constitutive KO, point mutation KI, reporter KI, quick KI, and general KI functionalities. In addition to these tailored solutions, genOway provides a comprehensive catalog of established models, such as humanized immune checkpoint mouse models, immunodeficient and reconstituted mouse and rat strains, humanized immune target models, various other pre-designed mouse and rat models, and immune checkpoint catalog cell lines. Serving a diverse range of clients, including pharmaceutical and life science companies as well as academic research institutions, genOway was founded in 1999 and is headquartered in Lyon, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
€0.31€0.00 (0.0%)
Nicox S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
€0.74+€0.07 (+10.45%)
Aelis Farma S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
€0.69+€0.02 (+2.53%)
Advicenne S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.64% below the high.
€0.17+€0.01 (+6.46%)
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
